Ros CRISPR Activation Plasmid (h): sc-402450-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Ros CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Ros CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Ros CRISPR Activation Plasmid (h) and Ros CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ROS1 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ros CRISPR Activation Plasmid (h) | sc-402450-ACT | 20 µg | $397.00 | |||
Ros CRISPR Activation Plasmid (h2) | sc-402450-ACT-2 | 20 µg | $397.00 |
Human ROS1 encodes Ros, a receptor tyrosine kinase that regulates cellular growth and differentiation through phosphorylation-dependent signaling. Upon activation, ROS1 engages canonical RTK pathways including MAPK/ERK, PI3K/AKT, and JAK/STAT, influencing proliferation, survival, and cytoskeletal dynamics. Aberrant ROS1 signaling, frequently via gene fusions or ectopic activation, is implicated in oncogenic transformation and tumor progression, making it a key node for studying RTK-driven transcriptional programs. ROS1 biology is also relevant for investigating receptor trafficking, kinase-domain regulation, and downstream network rewiring in cancer models.
Ros CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ROS1 expression without altering the underlying DNA sequence.
Ros CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ROS1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ROS1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Ros expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ROS1 locus and enabling the study of Ros-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Ros pathway restoration in tumor cells with silenced or reduced ROS1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.